Remove

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a

INFORMATION DISCLOSURE STATEMENT BY APPLICANT (Not for submission under 37 CFR 1.99)

	Application Number		10632174
	Filing Date		2003-07-31
	First Named Inventor	Craig	D. Johnson
	Art Unit		3672
	Examiner Name	Danie	el P. Stephenson
	Attorney Docket Number		68.0352

Examiner Initial*	Cite No	Patent Number	Kind Code ¹	Issue E	Date	Name of Patentee or Applicant		Pages,Columns,Lines where Relevant Passages or Relevan Figures Appear			
	1	5979551	A	1999-1	1-09	Uban, et al.					
If you wis	h to a	dd additional U.S. Pate	nt citatio	n inform	ation pl	lease click the	Add button.		Add		
			U.S.P	ATENT	APPLI	CATION PUB	LICATIONS		Remove		
Examiner Cite Initial*		Publication Number	Kind Code ¹				eited Desument		s,Columns,Lines where ant Passages or Relevant es Appear		
	1	20020020524	A1	2002-0	2-21	Gano					
	2	20020070031	A1	2002-0	6-13	Voll, et al.					
	3	20020092649	A1	2002-0	7-18	Boxenman, et	al.				
If you wis	h to a	dd additional U.S. Publi	shed Ap	plication	citatio	n information p	please click the Ad	d button	Add		
				FOREIG	SN PAT	ENT DOCUM	IENTS		Remove		
Examiner Initial*	Cite No	Foreign Document Number ³	Country Code ²		Kind Code ⁴	Publication Date	Name of Patente Applicant of cited Document	e or v	vhere Rel	or Relevant	Ts
	1	1152120	EP		A2	2001-07-11	Halliburton				

U.S.PATENTS

INFORMATION DISCLOSURE STATEMENT BY APPLICANT (Not for submission under 37 CFR 1.99) Examiner Name

Application Number		10632174
Filing Date		2003-07-31
First Named Inventor	Craig	D. Johnson
Art Unit		3672
Examiner Name Danie		P. Stephenson
Attorney Docket Numb	er	68.0352

	2	1167686	EP	A2	2002-01-02	Halliburton		
	3	2370301	GB	A	2002-06-26	Baker Hughes		
	4	2374098	GB	В	2005-03-30	Baker Hughes		
	5	2403491	GB GB	A	2003-06-11	Weatherford/Lamb		
	6	0188332	wo	A1	2001-11-22	Halliburton		
	7	03023185	wo	A1	2003-03-20	Shell		
	8	03100211	wo	A1	2003-12-04	Nagaoka		
If you wish to add additional Foreign Patent Document citation information please click the Add button Add								
NON-PATENT LITERATURE DOCUMENTS Remove								
Examiner Initials*	Examiner Cite Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (look, magazine, journal, sorial, symposium, catalog, etc), date, pages(s), volume-issue numbor(s), publisher, dity and/or country where published.							Т5
								-

If you wish to add additional non-patent literature document citation information please click the Add button Add

EFS Web 1.0.1

	Application Number		10632174
INFORMATION DIGGS COURT	Filing Date		2003-07-31
INFORMATION DISCLOSURE STATEMENT BY APPLICANT	First Named Inventor	Craig	D. Johnson
(Not for submission under 37 CFR 1.99)	Art Unit		3672
	Examiner Name Danie		el P. Stephenson
	Attorney Docket Numb	er	68.0352

	EXAMINER SIGNATURE		
Examiner Signature		Date Considered	
AEMANUNED: I-W-LW		W MIDED COO	D

citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

1 See Kinc Codes of USPTO Patient Documents at year USPTO_COD(or WREP 901.6.2 Each of files that issued to the document, by the hovietier code (WIPO Standard ST3.) 3 or duplanes plants obcuments, by man changes of the Preprint many procedule see serial number of the plants of the USPTO many processes are all number of the plants of the Company of th

INFORMATION DISCLOSURE STATEMENT BY APPLICANT (Not for submission under 37 CFR 1.99)

Application Number		10632174
Filing Date		2003-07-31
First Named Inventor	Craig	D. Johnson
Art Unit		3672
Examiner Name Danie		el P. Stephenson
Attorney Docket Number		68.0352

CERTIFICATION STATEMENT

Please see 37	CFR 1.97	and 1.98 to make	the appropriate	selection(s):
---------------	----------	------------------	-----------------	---------------

That each item of information contained in the information disclosure statement was first cited in any communication from a foreign patent office in a counterpart foreign application not more than three months prior to the filing of the information disclosure statement. See 3.7 CFR 1.97(eVI.)

OR

That no item of information contained in the information disclosure statement was cited in a communication from a foreign patent office in a counterpart to reign application, and, to the knowledge of the person signing the certification after making reasonable inquity, no item of information contained in the information disclosure statement was known to any individual designated in 37 CFR 155(c) more than three months prior to the filing of the information disclosure statement. See 37 CFR 197(c)(c)

- See attached certification statement.
- Fee set forth in 37 CFR 1.17 (p) has been submitted herewith.
- ☐ None

SIGNATURE

A signature of the applicant or representative is required in accordance with CFR 1.33, 10.18. Please see CFR 1.4(d) for the form of the signature.

_			
Signature	/Kevin P. McEnaney/	Date (YYYY-MM-DD)	2006-06-21
Name/Print	Kevin P. McEnanev	Registration Number	46258

This collection of information is required by 3T CFR 1.97 and 1.98. The information is required to obtain or retain a benefit by the public which is foll field end by the USPTO to process) an application. Confidentiality is governed by \$5 U.S. C.12 and 3T CFR 1.14. This collection is estimated to take 1 hour to complete, including gathering, preparing and submitting the completed application from the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademán Xfflor, U.S. Department of Commence, P. 0. Bot 1450, Alexandria, V.3231-1450, DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

Privacy Act Statement

The Privacy Act of 1974 (P.L. 93-579) requires that you be given certain information in connection with your submission of the attached form related to a patient application or patient. Accordingly, pursuant to the requirements of the Act, please be advised that. (1) the general authority for the collection of this information is 35 U.S.C. 2(b)(2); (2) famishing of the information solicided is voluntary, and (3) the principal purpose for which the information is used by the U.S. Patient and Trademan Kolfice is to process another examine your submission relation to a patient application or patient. If you do not furnish the requested process another examine your submission relation to a patient application or patient. If you do not furnish the requested the process another examine your submission, which may visually intermediate or of redesting to a submission or the basic log process another examine; your submission, which may visually intermediate or of redesting to a submission or the submission or the submission of the submission or the submission of the submission of the submission or the submission of the submission or the submission of the submission or the submission or the submission of the submission or the submission or the submission or the

The information provided by you in this form will be subject to the following routine uses:

- The information on this form will be treated confidentially to the extent allowed under the Freedom of Information Act (5 U.S.C. 552) and the Privacy Act (5 U.S.C. 552a). Records from this system of records may be disclosed to the Department of Justice to determine whether the Freedom of Information Act requires disclosure of these record s.
 - A record from this system of records may be disclosed, as a routine use, in the course of presenting evidence to a court, magistrate, or administrative tribunal, including disclosures to opposing counsel in the course of settlement neodiations.
 - A record in this system of records may be disclosed, as a routine use, to a Member of Congress submitting a request involving an individual, to whom the record partains, when the individual has requested assistance from the Member with respect to the subject matter of the record.
 - A record in this system of records may be disclosed, as a routine use, to a contractor of the Agency having need for the information in order to perform a contract. Recipients of information shall be required to comply with the requirements of the Privacy Act of 1974. as amended, pusuant to 5 U.S.C. 552a(m).
 - A record related to an International Application filed under the Patent Cooperation Treaty in this system of records
 may be disclosed, as a routine use, to the International Bureau of the World Intellectual Property Organization, pursuant
 to the Patent Cooperation Treaty.
 - A record in this system of records may be disclosed, as a routine use, to another federal agency for purposes of National Security review (35 U.S.C. 181) and for review pursuant to the Atomic Energy Act (42 U.S.C. 218(c)).
- 7. A record from this system of records may be disclosed, as a routine use, to the Administrator, General Services, or hisher designe, cuting an inspection of records concluded by GSAs a part of that apency's responsibility to recommend improvements in records management practices and programs, under suthority of 4d U.S.C. 2004 and 2006. Such disclosure shall be made in accordance with the GSA regulations governing inspection of records for this purpose, and any other relevant (i.e., GSA or Commerce) directive. Such disclosure shall not be used to make determinations about individuals.
- A record from this system of records may be disclosed, as a routine use, to the public after either publication of the application pursuant to 35 U.S. C. 122(b) or issuance of a patent pursuant to 35 U.S. C. 151. Further, a record may be disclosed, subject to the limitations of 37 CFR 1.14, as a routine use, to the public if the record via set float in an application which became abandomed or in which the proceedings were terminated and which application is referenced by either a published application, an application open to public inspections or an issuand patent.
 - A record from this system of records may be disclosed, as a routine use, to a Federal, State, or local law enforcement agency, if the USPTO becomes aware of a violation or potential violation of law or regulation.